Xiaojuan Li, PhD, MSPH is a pharmacoepidemiologist and Instructor in the Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute. She received her doctoral degree in Epidemiology from the University of North Carolina at Chapel Hill and completed a postdoctoral fellowship at the Department of Population Medicine.
Dr. Li’s research focuses on generating valid and actionable evidence regarding the uses, benefits, and harms of medical treatment from real-world data to inform clinical decisions and healthcare delivery. She has expertise in high-dimensional electronic healthcare databases, advanced pharmacoepidemiologic and causal inference methods, and comparative effectiveness research, and has extensive experience in their applications to assess effectiveness and safety of complex treatments.
Dr. Li has developed an innovative research program in Alzheimer’s disease and related dementias (ADRD), leveraging her expertise in pharmacoepidemiology and causal inference. She is currently leading multiple projects funded by the National Institutes of Health (NIH), including an observational study to optimize the use of symptomatic dementia drugs in persons living with ADRD (NIA R03AG070661) and an embedded pragmatic clinical trial, Co-CARE-AD, to evaluate the effectiveness of a multicomponent care coordination program for community-dwelling individuals living with ADRD and their care partners.
Dr. Li is also supported by an NIH Career Development Award focused on optimizing care for older adults in the new treatment era for type 2 diabetes and heart failure (NIA K01AG073651).